Novavax Inc (NVAX) 13.86usd ,-0.17 , -1.21%
Novavax has been going down lately because like any other clinical-stage it has some risk involved and the biggest risk right now that the investors are thinking of is that it will probably fail to get the approval from the FDA that is why today it is trading on 13.86usd. This is because 11 percent of regulatory filings for infectious disease candidates wind up have been turned down by the FDA and also it is not the only candidate working on the drug for Covid 19 so it might lose or win since there is a competition and the investors are becoming uncertain about it.